Company intelligence / Profile preview

Overture Life

Madrid / Alcobendas, Spainoverture.life ↗

Ownership: Private
Development stage: Preclinical

Overview

Overture Life has demonstrated improved oocyte survival rates in early clinical evaluations using its DaVitri automated vitrification system. The company reports two healthy live births resulting from its technology. Its m|z AI-powered test has received a U.S. CLIA license, supporting regulatory-grade validation.

Therapeutic areas: Women's Health
Modalities: Device (automation platforms for embryology/IVF)Artificial Intelligence (AI-powered embryo selection test)Microfluidics (used in automation platform)Software (proprietary software for IVF automation)Robotics (robotic automation of lab procedures)
Industry: Metabolite Diagnostics

Partnerships

Not specifically disclosed; backers include major venture investors but no explicit pharma/biotech partnerships listed as of June 2025.

Beyond the preview

Go deeper on Overture Life.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Overture Life.

Explore the full profile